Trial reportFrontiers of medicine2014
Effects of comprehensive therapy based on traditional Chinese medicine patterns on older patients with chronic obstructive pulmonary disease: a subgroup analysis from a four-center, randomized, controlled study.
Trial report in Frontiers of medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- A multicenter randomized controlled trial and metabolomics exploration of Traditional Chinese Medicine pattern-based therapy for stable chronic obstructive pulmonary disease.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026Trial
- Clinical efficacy of comprehensive therapy based on traditional Chinese medicine patterns on patients with pneumoconiosis: a pilot double-blind, randomized, and placebo-controlled study.Frontiers of medicine · 2022Trial
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- [Protective effect ofNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Article
- The Effective Compound Combination of Bufei Yishen Formula III Improves the Mitochondrial Dysfunction via Inhibiting JNK/Sab Pathway in COPD Mice.Drug design, development and therapy · 2025Article
- Article
- Effects of co-application of tiotropium bromide and traditional Chinese medicine on patients with stable chronic obstructive pulmonary disease: a muilticenter, randomized, controlled trial study.Frontiers in medicine · 2024Article
- Effects of the Chinese herbal formula San-Huang Gu-Ben Zhi-Ke treatment on stable chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial.Frontiers in pharmacology · 2023Article
- Effective-Component Compatibility of Bufei Yishen Formula III Combined with Electroacupuncture Suppresses Inflammatory Response in Rats with Chronic Obstructive Pulmonary Disease via Regulating SIRT1/NF-BioMed research international · 2022Article
- The Clinical Efficiency and the Mechanism of Sanzi Yangqin Decoction for Chronic Obstructive Pulmonary Disease.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Article
- Effect of Radix Stemonae concentrated decoction on the lung tissue pathology and inflammatory mediators in COPD rats.BMC complementary and alternative medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the efficacy of comprehensive therapy based on traditional Chinese medicine (TCM) patterns on older patients with chronic obstructive pulmonary disease (COPD) through a fourcenter, open-label, randomized controlled trial. Patients were divided into the trial group treated using conventional western medicine and Bu-Fei Jian-Pi granules, Bu-Fei Yi-Shen granules, and Yi-Qi Zi-Shen granules based on TCM patterns respectively; and the control group treated using conventional western medicine. A total of 136 patients ≥ 65 years completed the study, with 63 patients comprising the trial group and 73 comprising the control group. After the six-month treatment and the 12-month follow-up period, significant differences were observed between the trial and control groups in the following aspects: frequency of acute exacerbation (P ≤ 0.040), duration of acute exacerbation (P = 0.034), symptoms (P ≤ 0.034), 6-min walking distance (6MWD) (P ≤ 0.039), dyspnea scale (P ≤ 0.036); physical domain (P ≤ 0.019), psychological domain (P ≤ 0.033), social domain (P ≤ 0.020), and environmental domain (P ≤ 0.044) of the WHOQOL-BREF questionnaire; and daily living ability domain (P ≤ 0.007), social activity domain (P ≤ 0.018), depression symptoms domain (P ≤ 0.025), and anxiety symptoms domain (P ≤ 0.037) of the COPD-QOL. No differences were observed between the trial and control groups with regard to FVC, FEV1, and FEV1%.
Indexed as
Identifiers
25204290What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.